[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SI1888107T1 - Nove formulacije cepiv - Google Patents

Nove formulacije cepiv

Info

Publication number
SI1888107T1
SI1888107T1 SI200631384T SI200631384T SI1888107T1 SI 1888107 T1 SI1888107 T1 SI 1888107T1 SI 200631384 T SI200631384 T SI 200631384T SI 200631384 T SI200631384 T SI 200631384T SI 1888107 T1 SI1888107 T1 SI 1888107T1
Authority
SI
Slovenia
Prior art keywords
vaccine formulations
novel vaccine
novel
formulations
vaccine
Prior art date
Application number
SI200631384T
Other languages
English (en)
Inventor
Alexis Guy Andre Parisot
Stephanie Marie-Catherine Desgouilles-Blechet
Catherine Charreyre
Claude Jean Marie Roulet
Original Assignee
Merial Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Ltd filed Critical Merial Ltd
Publication of SI1888107T1 publication Critical patent/SI1888107T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
SI200631384T 2005-04-15 2006-04-13 Nove formulacije cepiv SI1888107T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/107,000 US7691368B2 (en) 2005-04-15 2005-04-15 Vaccine formulations
EP06740939A EP1888107B1 (en) 2005-04-15 2006-04-13 Novel vaccine formulations
PCT/US2006/013936 WO2006113373A2 (en) 2005-04-15 2006-04-13 Novel vaccine formulations

Publications (1)

Publication Number Publication Date
SI1888107T1 true SI1888107T1 (sl) 2012-09-28

Family

ID=36950184

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200631384T SI1888107T1 (sl) 2005-04-15 2006-04-13 Nove formulacije cepiv

Country Status (25)

Country Link
US (1) US7691368B2 (sl)
EP (2) EP2422809A1 (sl)
JP (1) JP5093902B2 (sl)
KR (1) KR101292874B1 (sl)
CN (1) CN101184501A (sl)
AR (1) AR053360A1 (sl)
AU (2) AU2006236711B2 (sl)
BR (1) BRPI0610633B1 (sl)
CA (1) CA2604432C (sl)
CY (1) CY1113104T1 (sl)
DK (1) DK1888107T3 (sl)
ES (1) ES2389377T3 (sl)
HK (1) HK1116085A1 (sl)
IL (1) IL186600A (sl)
MX (1) MX2007012785A (sl)
MY (1) MY144189A (sl)
NZ (2) NZ584420A (sl)
PL (1) PL1888107T3 (sl)
PT (1) PT1888107E (sl)
RU (1) RU2422155C2 (sl)
SI (1) SI1888107T1 (sl)
TW (1) TWI376232B (sl)
UA (1) UA94404C2 (sl)
WO (1) WO2006113373A2 (sl)
ZA (1) ZA200708634B (sl)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
DK1926496T3 (da) * 2005-09-09 2013-09-30 Intervet Int Bv PCV-2-vaccine
WO2007052055A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
JP2009514839A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル サイトカイン誘導剤を含むアジュバントインフルエンザワクチン
JP2009514850A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル アジュバントとして減少した量の水中油型エマルションを有するインフルエンザワクチン
EP3127551B1 (en) * 2005-12-29 2020-07-29 Boehringer Ingelheim Animal Health USA Inc. Pcv2 immunogenic composition for lessening clinical symptoms in pigs
CA2635598C (en) * 2005-12-29 2020-10-13 Boehringer Ingelheim Vetmedica, Inc. Multivalent pcv2 immunogenic compositions and methods of producing such compositions
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
US20080014221A1 (en) * 2006-03-03 2008-01-17 Royer Gregory C Mycoplasma hyopneumoniae vaccine
CA2646349A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
US20100010199A1 (en) 2006-09-11 2010-01-14 Novartis Ag Making influenza virus vaccines without using eggs
EP2099927A4 (en) * 2006-11-22 2010-05-05 Boehringer Ingelheim Vetmed METHODS FOR REDUCING FLAMBEES OF DISEASES ASSOCIATED WITH PORCINIC CIRCOVIRUS
CA2671629C (en) 2006-12-06 2017-08-15 Novartis Ag Vaccines including antigen from four strains of influenza virus
EP2101815A4 (en) * 2006-12-11 2010-10-06 Boehringer Ingelheim Vetmed EFFICIENT PROCESS FOR THE TREATMENT OF PORCINE CIRCOVIRUS AND LAWSONIA INTRACELLULARIS INFECTIONS
RU2520087C2 (ru) * 2006-12-15 2014-06-20 Бёрингер Ингельхайм Ветмедика, Инк. Лечение свиней с помощью антигена pcv2
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
NZ580978A (en) 2007-04-06 2012-07-27 Inviragen Inc Methods and compositions for live attenuated viruses
NZ582595A (en) 2007-06-27 2012-07-27 Novartis Ag Low-additive influenza vaccines
US20090017064A1 (en) * 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
US7829274B2 (en) * 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
CN101951949B (zh) 2007-10-19 2013-10-02 诺华股份有限公司 脑膜炎球菌疫苗制剂
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
PT2224951T (pt) * 2007-12-21 2020-01-10 Zoetis Services Llc Bacterinas tratadas termicamente e vacinas de emulsão preparadas a partir de tais bacterinas tratadas termicamente
US20110020394A1 (en) * 2007-12-31 2011-01-27 Boehringer Ingelheim Vetmedica, Inc. Pcv2 orf2 virus like particle with foreign amino acid insertion
EP2242511A4 (en) * 2008-01-23 2012-10-24 Boehringer Ingelheim Vetmed IMMUNOGENIC COMPOSITIONS OF MYCOPLASMA HYOPNEUMONIAE PCV2, AND METHODS FOR PRODUCING SUCH COMPOSITIONS
JP5518041B2 (ja) 2008-03-18 2014-06-11 ノバルティス アーゲー インフルエンザウイルスワクチン抗原の調製における改良
AU2009277107B2 (en) * 2008-07-30 2014-02-27 University Of Kentucky Research Foundation Equine disease model for herpesvirus neurologic disease and uses thereof
CA2737455A1 (en) 2008-09-18 2010-03-25 Novartis Ag Vaccine adjuvant combinations
KR101715415B1 (ko) 2008-11-28 2017-03-10 메리얼 인코포레이티드 재조합 조류 인플루엔자 백신 및 그의 용도
US20120093860A1 (en) 2009-02-10 2012-04-19 Novartis Ag Influenza vaccines with increased amounts of h3 antigen
KR20110132373A (ko) 2009-02-10 2011-12-07 노파르티스 아게 유행병-연관 주에 대한 인플루엔자 백신 요법
CN102307590A (zh) 2009-02-10 2012-01-04 诺华有限公司 具有减少量的角鲨烯的流感疫苗
CN102438650A (zh) 2009-03-06 2012-05-02 诺华有限公司 衣原体抗原
EP2228054A1 (en) * 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
RU2555757C2 (ru) 2009-03-24 2015-07-10 Новартис Аг Комбинации менингококкового фактор н-связывающего белка и пневмококковых сахаридных конъюгатов
EP2510947B1 (en) 2009-04-14 2016-02-10 GlaxoSmithKline Biologicals SA Compositions for immunising against Staphylococcus aureus
EP2453913B1 (en) * 2009-05-19 2016-06-22 Bioproperties Pty Ltd A temperature sensitive vaccine strain of mycoplasma hyopneumoniae and uses thereof
EP2401384B1 (en) 2009-05-21 2012-10-03 Novartis AG Reverse genetics using non-endogenous pol i promoters
CN103764160A (zh) 2009-05-29 2014-04-30 诺华有限公司 流感病毒血凝素试验
WO2011004263A2 (en) 2009-07-07 2011-01-13 Novartis Ag Conserved escherichia coli immunogens
PL2464658T3 (pl) 2009-07-16 2015-03-31 Novartis Ag Immunogeny z Escherichia coli o zniesionej toksyczności
EP2459708B1 (en) * 2009-07-31 2016-06-22 National Research Council of Canada H. pylori lipopolysaccharide outer core epitope
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
CN107213461B (zh) * 2009-09-10 2022-03-15 勃林格殷格翰动物保健美国公司 包含含有皂苷的佐剂的新疫苗制剂
KR20120081587A (ko) 2009-09-10 2012-07-19 노파르티스 아게 기도 질병에 대한 조합 백신
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
CN102724988B (zh) 2009-09-30 2014-09-10 诺华股份有限公司 脑膜炎球菌fHBP多肽的表达
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
ES2454815T3 (es) 2009-10-20 2014-04-11 Novartis Ag Métodos mejorados de genética inversa para la recuperación de virus
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
ES2707778T3 (es) 2009-12-30 2019-04-05 Glaxosmithkline Biologicals Sa Inmunógenos polisacáridos conjugados con proteínas portadoras de E. coli
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
EP2547357A1 (en) 2010-03-18 2013-01-23 Novartis AG Adjuvanted vaccines for serogroup b meningococcus
FR2957933B1 (fr) * 2010-03-24 2012-04-27 Seppic Sa Vaccin vivant pour maladies aviaires
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
US9744228B2 (en) 2010-04-07 2017-08-29 Norvartis Ag Method for generating a parvovirus B19 virus-like particle
JP5815676B2 (ja) 2010-04-30 2015-11-17 テマセック・ライフ・サイエンシズ・ラボラトリー・リミテッド Ｈ５ｎ１系列に対する汎用ワクチン
ES2559445T3 (es) * 2010-05-11 2016-02-12 Intervet International B.V. Vacuna contra Mycoplasma hyopneumoniae apta para la administración en presencia de anticuerpos de origen materno
CA2800150C (en) 2010-05-21 2018-09-04 Novartis Ag Influenza virus reassortment method
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
EP2585106A1 (en) 2010-06-25 2013-05-01 Novartis AG Combinations of meningococcal factor h binding proteins
JP2013533745A (ja) 2010-07-06 2013-08-29 ノバルティス アーゲー ノロウイルスに由来する免疫原性組成物および方法
GB201017519D0 (en) 2010-10-15 2010-12-01 Novartis Vaccines Inst For Global Health S R L Vaccines
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
AU2012222883A1 (en) 2011-03-02 2013-10-17 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
US10030052B2 (en) 2011-07-25 2018-07-24 Glaxosmithkline Biologicals Sa Parvovirus Vp1 unique region polypeptides and compositions thereof
CN103917245B (zh) 2011-09-14 2017-06-06 葛兰素史密丝克莱恩生物有限公司 用于制备糖‑蛋白质糖缀合物的方法
EP2768528A1 (en) 2011-10-20 2014-08-27 Novartis AG Adjuvanted influenza b virus vaccines for pediatric priming
EP2791680B1 (en) 2011-12-12 2015-12-09 Novartis AG Assay for influenza virus hemagglutinins
EP2793939A1 (en) 2011-12-23 2014-10-29 Novartis AG Stable compositions for immunising against staphylococcus aureus
WO2013123219A1 (en) * 2012-02-14 2013-08-22 Merial Limited Rotavirus subunit vaccines and methods of making and use thereof
CA2813723A1 (en) 2012-03-02 2013-09-02 Novartis Ag Influenza virus reassortment
CA2875752A1 (en) 2012-06-04 2013-12-12 Novartis Ag Improved safety testing
CN104582723A (zh) 2012-08-31 2015-04-29 诺华股份有限公司 用于针对金黄色葡萄球菌的免疫的稳定化的蛋白质
US9926344B2 (en) 2012-08-31 2018-03-27 Glaxosmithkline Biologicals Sa Stabilised proteins for immunising against Staphylococcus aureus
EP2943219B1 (en) 2012-09-10 2021-12-15 Szathmary, Dr. Susan Vaccine to prevent mycoplasmal infection in waterfowl
MX363529B (es) 2012-09-18 2019-03-27 Novartis Ag Vesículas de membrana externa.
CA2885625A1 (en) 2012-10-02 2014-04-10 Glaxosmithkline Biologicals S.A. Nonlinear saccharide conjugates
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
SG11201504258RA (en) 2012-11-30 2015-07-30 Glaxosmithkline Biolog Sa Pseudomonas antigens and antigen combinations
WO2014086732A2 (en) 2012-12-03 2014-06-12 Novartis Ag Influenza virus reassortment
MX2015011529A (es) 2013-03-13 2016-02-05 Novartis Ag Reordenamiento del virus de infuenza b.
EP2994162B1 (en) 2013-05-08 2021-04-07 Pharmgate Biologics Inc. Vaccine for pcv2 and mycoplasma
JP2016521282A (ja) 2013-05-10 2016-07-21 ノバルティス アーゲー インフルエンザワクチンにおけるナルコレプシーのリスクの回避
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
CN105722976A (zh) 2013-06-06 2016-06-29 诺华股份有限公司 流感病毒重配
MX2016004063A (es) 2013-10-02 2016-06-06 Boehringer Ingelheim Vetmed Variante de la proteina pcv2 orf2 y particulas similares al virus compuestas por esta.
JP6605469B2 (ja) * 2013-12-03 2019-11-13 インターベット インターナショナル ベー． フェー． ブタサーコウイルス２型に対するワクチン
CN103751779A (zh) * 2014-02-25 2014-04-30 中国农业科学院上海兽医研究所 O型口蹄疫多肽的泊洛沙姆凝胶佐剂
RS59971B1 (sr) 2014-03-26 2020-03-31 Glaxosmithkline Biologicals Sa Mutantni stafilokokni antigeni
US9713639B2 (en) 2014-05-19 2017-07-25 Merial, Inc. Recombinant spike protein subunit based vaccine for porcine epidemic diarrhea virus (PEDV)
US20150359880A1 (en) * 2014-06-16 2015-12-17 Biomune Company Dual adjuvant vaccine compositions, preparation and uses
CN105267962A (zh) * 2014-06-18 2016-01-27 潘皓 纳米乳疫苗辅剂
JP2015120709A (ja) * 2015-01-09 2015-07-02 ラボラトリオ アヴィメキシコ エスエー ディーイー シーヴィーＬａｂｏｒａｔｏｒｉｏ Ａｖｉ−Ｍｅｘ，Ｓ．Ａ． Ｄｅ Ｃ．Ｖ． 遺伝子組み換え不活性化ウィルスベクターワクチン
CA2990633A1 (en) 2015-06-26 2016-12-29 Merial, Inc. Inactivated canine influenza vaccines and methods of making and uses thereof
AU2016281904B2 (en) 2015-06-26 2022-08-11 Seqirus UK Limited Antigenically matched influenza vaccines
BR112018000296A2 (pt) 2015-07-07 2018-09-04 Seqirus UK Limited ensaios de potência de influenza
BR112018007093A2 (pt) 2015-10-08 2019-01-15 Pasteur Institut vacina heteróloga atentada viva para leptospirose
EP3380119B1 (en) 2015-11-23 2021-08-25 Boehringer Ingelheim Animal Health USA Inc. Fmdv and e2 fusion proteins and uses thereof
TWI760322B (zh) 2016-01-29 2022-04-11 美商百靈佳殷格翰動物保健美國有限公司 重組腺病毒載體裝載之fmdv疫苗及其用途
JOP20190088A1 (ar) 2016-10-21 2019-04-21 Us Agriculture نواقل مؤتلفة للتعبير عن مولدات مضاد فيروس انفلونزا الطيور و استخداماتها
EP3548077A1 (en) * 2016-11-29 2019-10-09 Intervet International B.V. Swine vaccine
CN117357641A (zh) 2016-12-14 2024-01-09 勃林格殷格翰动物保健美国公司 表达禽病原体的多种抗原的重组hvt载体及其用途
FR3092754B1 (fr) * 2019-02-18 2022-06-03 Total Marketing Services Composition adjuvante pour vaccin
EP4061930A1 (en) 2019-11-18 2022-09-28 Seqirus Pty Ltd Method for producing reassortant influenza viruses
CN113546162B (zh) * 2021-05-31 2023-07-18 江苏省农业科学院 一种支原体疫苗及其制备方法
WO2024133656A1 (en) 2022-12-22 2024-06-27 Ceva Sante Animale Oil adjuvant compositions and vaccine emulsions comprising such oil adjuvant compositions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250289A (en) * 1987-07-24 1993-10-05 The Boots Company Plc Sunscreen compositions
US5376369A (en) * 1987-11-03 1994-12-27 Syntex (U.S.A.) Inc. Vaccine adjuvant
PL155558B1 (pl) * 1988-01-28 1991-12-31 Inst Ciezkiej Syntezy Orga Sposób wytwarzania kompozycji emulgującej
JP3187419B2 (ja) 1990-05-29 2001-07-11 アメリカン・サイアナミド・カンパニー ブタ肺炎ワクチンおよびその製造方法
US6197311B1 (en) * 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
US5846805A (en) 1991-08-26 1998-12-08 Boehringer Ingelheim Animal Health, Inc. Culture of swine infertility and respiratory syndrome virus in simian cells
US5338543A (en) 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
US5695766A (en) 1992-10-30 1997-12-09 Iowa State University Research Foundation Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome
AU681874B2 (en) 1993-02-08 1997-09-11 Bayer Corporation Process for growing porcine reproductive and respiratory syndrome virus and its use in vaccines
FR2723740B1 (fr) 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
US5985177A (en) 1995-12-14 1999-11-16 Shiseido Co., Ltd. O/W/O type multiple emulsion and method of preparing the same
US5866401A (en) 1996-03-01 1999-02-02 Schering Corporation Porcine reproductive and respiratory syndrome vaccine
US5980912A (en) 1997-03-25 1999-11-09 Zonagen, Inc. Chitosan induced immunopotentiation
US6391314B1 (en) 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
US20030165545A1 (en) * 2002-01-30 2003-09-04 Allergan, Inc. Ophthalmic compositions including oil-in-water emulsions, and methods for making and using same
UA84024C2 (ru) 2003-07-24 2008-09-10 Мериал Лимитед Новые вакцинные композиции, которые содержат эмульсию типа "масло в воде"
US9390965B2 (en) 2013-12-20 2016-07-12 Taiwan Semiconductor Manufacturing Co., Ltd. Air-gap forming techniques for interconnect structures

Also Published As

Publication number Publication date
CA2604432A1 (en) 2006-10-26
BRPI0610633B1 (pt) 2021-07-20
TW200716165A (en) 2007-05-01
AR053360A1 (es) 2007-05-02
RU2007142202A (ru) 2009-05-20
JP2008536860A (ja) 2008-09-11
IL186600A (en) 2014-05-28
EP1888107B1 (en) 2012-06-13
BRPI0610633A2 (pt) 2010-07-13
CA2604432C (en) 2013-06-11
CY1113104T1 (el) 2016-04-13
JP5093902B2 (ja) 2012-12-12
IL186600A0 (en) 2008-01-20
RU2422155C2 (ru) 2011-06-27
HK1116085A1 (en) 2008-12-19
PL1888107T3 (pl) 2012-11-30
EP1888107A2 (en) 2008-02-20
WO2006113373A2 (en) 2006-10-26
WO2006113373A3 (en) 2007-02-01
AU2010206041B2 (en) 2012-08-02
MY144189A (en) 2011-08-15
ZA200708634B (en) 2008-10-29
DK1888107T3 (da) 2012-07-23
US20060233831A1 (en) 2006-10-19
KR20070122550A (ko) 2007-12-31
AU2006236711A1 (en) 2006-10-26
AU2006236711B2 (en) 2010-07-29
UA94404C2 (ru) 2011-05-10
PT1888107E (pt) 2012-07-26
ES2389377T3 (es) 2012-10-25
TWI376232B (en) 2012-11-11
US7691368B2 (en) 2010-04-06
KR101292874B1 (ko) 2013-08-05
MX2007012785A (es) 2008-01-11
AU2010206041A1 (en) 2010-08-19
NZ562663A (en) 2010-04-30
NZ584420A (en) 2011-11-25
EP2422809A1 (en) 2012-02-29
CN101184501A (zh) 2008-05-21

Similar Documents

Publication Publication Date Title
IL186600A0 (en) Novel vaccine formulations
IL192084A0 (en) Vaccine
GB0504436D0 (en) Vaccine
GB0505909D0 (en) Formulations
ZA200709518B (en) Vaccine composition
EP1909584A4 (en) PRENYLFLAVONOID FORMULATIONS
GB0505569D0 (en) Formulations
ZA200802953B (en) Solid vaccine formulation
ZA200709207B (en) Vaccine
GB0504940D0 (en) Vaccine formulation
GB0515135D0 (en) Vaccine
GB0810662D0 (en) Vaccine
ZA200709210B (en) Vaccine
GB0516944D0 (en) Vaccine
GB0526412D0 (en) Vaccine
GB0519090D0 (en) Novel formulations
GB0500912D0 (en) Novel formulations
GB0500913D0 (en) Novel formulations
GB0500915D0 (en) Novel formulations
GB0500917D0 (en) Novel formulations
GB0504106D0 (en) Novel formulations
GB0522828D0 (en) Novel formulations
GB0502569D0 (en) Vaccine composition
GB0526232D0 (en) Vaccine
GB0523445D0 (en) Vaccine